세계의 심장내 초음파 기기 시장(2023-2030년)

Overview

Intracardiac Echocardiography (ICE) utilizes sound waves to construct pictures of the heart in the exact manner that a transthoracic or "standard" echocardiogram accomplishes. Nevertheless, with intracardiac echocardiography, a small catheter with an ultrasound sensor is inserted into the heart where perfect pictures of the heart can be acquired to aid in diatinct cardiological condition diagnosis and management.

The Intracardiac Echocardiography (ICE) is a unique catheter imaging technology usually utilized to aid closure techniques for atrial septal defects (ASD), patent foramen ovale (PFO), and ventricular septal defects (VSD), interventions exclusively conducted as open-heart surgical operations a few years ago. Intracardiac echocardiography is vastly employed to direct transcatheter interventions for structural cardiac disorder and arrhythmia, to streamline procedural success and minimize intricacies.

The growing cases of cardiovascular disorders, market developments including mergers, acquisitions, products introductions among others, growing awareness among other factors are expected to boost the global intracardiac echocardiography devices market growth in the forecast period. Further, the growing research activities, technological advancements and with fundings in intracardiac echocardiography devices are also expected to contribute to the global market growth in the forecast period.

Dynamics

Increasing Prevalence of Cardiovascular Disorders

The growing cases of cardiovascular condition is among the primary factor that is expected to boost the global market growth in the forecast period. For instance, according to the European Cardiovascular Society, over 12.6 million individuals suffer from CVD each year in ESC-associated nations. The cardiovascular condition is the top reason for mortality (39%) among men in ESC member nations while 2.2 million females die because of cardiovascular condition annually in ESC associate nations around 40% of women die from CVD in the EU.

Also, according to the British Heart Foundation Released UK Factsheet in April 2023, around 7.6 million individuals are living with heart and circulatory disorders in the UK, aging and growing inhabitants and enhanced survival rates from heart and circulatory events could witness these numbers advance still additionally. About 4 million men and over 3.6 million women are living with heart and circulatory conditions in the UK, it is estimated that in the UK over half of inhabitants will encounter heart or circulatory disorders in their lifespan.

Moreover, approximately double the number of individuals living with heart and circulatory conditions in the UK compared to the number of cancer and Alzheimer's conditions cases added. Heart and circulatory disorders generate about 25% of all deaths in the UK; that's over 160,000 deaths annually, or 460 every day accounting for one death every three minutes, roughly 48,000 individuals below the age of 75 in the UK die because of heart and circulatory disorders every year.

Increasing Number of Product Approvals

The rising number of product approvals by distinct regulatory authorities is also expected to contribute to the global intracardiac echocardiography devices market growth during the forecast period. For instance, in April 2022, Franklin Mountain Medical obtained FDA authorization for its patented UltraNav Transseptal Catheter System a dual-lumen catheter that allows side-by-side, concurrent delivery of both ICE and transseptal needles or catheters via one dual-lumen device for steady access and delivery of cardiovascular catheters and guidewires to the cardiac chambers through transseptal puncture.

Similarly, in June 2021, Siemens Healthineers acquired CE Mark for the AcuNav Volume ICE (Intracardiac Echocardiography) catheter, a therapy-enabling imaging guide that delivers real-time, wide-angle visualization of cardiac anatomy in Structural Heart and Electrophysiology operations. AcuNav Volume ICE was the market's foremost Volume ICE catheter, designed based on 20 years of innovation record in ICE.

High Intracardiac Echocardiography Device Cost

The high intracardiac echocardiography devices and catheter costs are expected to be hampering the global Intracardiac Echocardiography Devices market growth during the forecast period. For instnace, the cost of a phased-array ICE catheter varies from $2,000 to $2,500, based on the volume of catheters bought. Similarly, the average list cost of cardiac 3D mapping systems varies from USD 250,000 to 800,000.

Likewise, Boston Scientific's iLAB Ultrasound Imaging System for Intracardiac Imaging costs around $131,400. Further, the average cost of a intracardiac echocardiography catheter system (USD 2000-2500) is an important barrier to the general usage of intracardiac echocardiography, slowing the global intracardiac echocardiography devices market demand in the forecast period.

Cardiologists Workforce Shortage

The cardiologists' workforce gap is expected to hamper the global intracardiac echocardiography devices market growth during the forecast period. For instance, according to the American College of Cardiology Foundation with not sufficient clinicians available to satisfy the requirements of an ever-growing patient population, the cardiology specialty domain is on the cusp of a concern. Similarly, according to the European Society of Cardiology in high-income nations, the median number of cardiologists per million inhabitants was 99.0 compared with 61.1 in middle-income nations.

Further, according to the Cardiologists Society of India (CSI), there are merely 5500 cardiologists in the country with a population of 1.3 billion, and there is only one cardiologist for the 30, 000 inhabitants in the nation. Again, according to a recent investigation from the Association of American Medical Colleges (AAMC), by 2034, the nation is predicted to be lacking anywhere from 37,000 to 124,000 medics. This contains a deficit of 17,000 to 48,000 primary care doctors and 3,000 to 13,000 experts, a category that encloses cardiologists.

Segment Analysis

The global intracardiac echocardiography devices market is segmented based on product type, imaging type, application, end-user and region.

3D Imaging Type Expected to Dominate Market

The increasing adoption of 3D intracardiac echocardiography (ICE) is expected to boost segmental growth enabling the segment to hold a majority of market share in the forecast period. For instance, in September 2022, Baptist Health's Miami Cardiac and Vascular Institute employed the VeriSight Pro, a real-time 3D intracardiac echocardiography catheter from Philips. The technology delivers exceptional 2D and 3D live imaging suggestions for a broad spectrum of cardiac operations in structural heart conditions.

Similarly, in December 2021, the Children's Hospital Colorado (Children's Colorado) was the foremost pediatric clinic in the globe to employ a 3D intracardiac echocardiography (ICE) catheter in the therapy of congenital heart conditions in the Cardiac Catheterization Lab. The live, 3D picture direction delivered by the FDA-authorized technology from Phillips permits cardiac interventionalists to sufficiently guide complicated operations, which is anticipated to result in enhanced outputs.

Geographical Penetration

Increasing Number of Cardiovascular Disorders Cases in North America

Owing to the growing cases of cardiovascular diseases in North America the region is expected to dominate the global market throughout the forecast period. For instance, according to the CDC, cardiac condition is the top reason for mortality of males, females, and individuals of most ethnical and racial levels in the United States, one individual dies every 33 seconds in the United States from cardiovascular condition.

Similarly, almost 695,000 individuals in the United States died from heart conditions in 2021 accounting for 1 in every 5 deaths. Further, the heart condition cost the United States around $239.9 billion annually from 2018 to 2019, which includes the expense of healthcare assistance, medications, and failed productivity because of death. Further, the American Heart Association has published the Heart and Stroke Statistics 2022 Update, according to that report, cardiac arrest remains a public health emergency as are over 356,000 out-of-hospital cardiac arrests (OHCA) yearly in the U.S., and almost 90% of them are deadly.

The incidence of EMS-assessed non-traumatic OHCA in individuals of any age is assessed to be 356,461, or almost 1,000 individuals every day. Survival to hospital release after EMS-treated cardiac arrest declines by approximately 10%. Additionally, in 2022, an estimated 655,000 Americans were expected to die because of heart conditions, and over 140,000 were expected to die from stroke. Accounting for one in every four deaths in the U.S. Heart condition and stroke also account for over $320 billion in healthcare expenses and failed productivity per year.

COVID-19 Impact Analysis

The COVID-19 pandemic had deep effects on cardio-pulmonary health and healthcare delivery. Direct effects enclosed information on myopericarditis jointly with highly regular information on pneumonia and pulmonary fibrosis, periodically advancing to respiratory collapse and demise. Additionally unpredictable, nevertheless, were the indirect effects of the pandemic on CV examinations and hospital admissions which have repeatedly demonstrated varying drops.

While there has been no indication of actual declines in the preponderance of CVD or the incidence of acute coronary syndromes, these reductions have extended considerations that the pandemic has directed to general under-investigation and under-treatment of many individuals. Indeed, reports from respective nations suggest substantial declines in investigative procedures for heart failure and coronary and electrophysiological conditions in 2020 corresponded with 2019. Declines in hospital admissions for a degree of CV conditions, including ST-elevation myocardial infarction, have even been registered in the same period.

By Product Type

• Radial or Rotating ICE
• Phased-array ICE

By Imaging Type

• 2D imaging
• 3D Imaging
• 4D Imaging

By Application

• Electrophysiology
• Left Atrial Appendage Closure
• Transcatheter Aortic Valve Implantation
• MitraClip Implantation and Mitral Valvuloplasty
• Other

By End-User

• Hospitals
• Specialty Clinics
• Diagnostic Centers
• Other

By Region

• North America
  • U.S.
  • Canada
  • Mexico

• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe

• South America
  • Brazil
  • Argentina
  • Rest of South America

• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific

• Middle East and Africa

Key Developments

• In March 2022, Seimens Healthineers introduced the next-generation AcuNav Volume four-dimensional (4D) intracardiac echocardiography (ICE) catheter in the United States.
• In April 2022, Franklin Mountain Medical obtained FDA authorization for its patented UltraNav Transseptal Catheter System for regulated access and delivery of cardiovascular catheters and guidewires to the heart chambers via transseptal puncture.

Competitive Landscape

The major global players in the market include Johnson & Johnson Services Inc., GE HealthCare, Koninklijke Philips N.V., Siemens Healthcare, Abbott Laboratories, Boston Scientific Corporation, Infraredx Inc., Terumo Corporation, ESAOTE SPA, and Conavi Medical among others.

Why Purchase the Report?

• To visualize the global intracardiac echocardiography devices market segmentation based on product type, imaging type, application, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of intracardiac echocardiography devices market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key product of all the major players.

The global intracardiac echocardiography devices market report would provide approximately 61 tables, 58 figures and 186 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product Type
• 3.2. Snippet by Imaging Type
• 3.3. Snippet by Application
• 3.4. Snippet by End-User
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Prevalence of Cardiovascular Disorders
    • 4.1.1.2. Increasing Number of Product Approvals
  • 4.1.2. Restraints
    • 4.1.2.1. High Intracardiac Echocardiography Device Cost
    • 4.1.2.2. Cardiologists Workforce Shortage
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Patent Analysis
• 5.6. Technology Trend
• 5.7. End-User Trend
• 5.8. SWOT Analysis
• 5.9. Russia-Ukraine War Impact
• 5.10. DMI Opinion

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID
  • 6.1.2. Scenario During COVID
  • 6.1.3. Scenario Post COVID
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Product Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 7.1.2. Market Attractiveness Index, By Product Type
• 7.2. Radial or Rotating ICE*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Phased-array ICE

8. By Imaging Type

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.1.2. Market Attractiveness Index, By Product Type
• 8.2. 2D Imaging*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. 3D Imaging
• 8.4. 4D Imaging

9. By Application

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.1.2. Market Attractiveness Index, By Application
• 9.2. Electrophysiology*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Left Atrial Appendage Closure
• 9.4. Transcatheter Aortic Valve Implantation
• 9.5. MitraClip Implantation and Mitral Valvuloplasty
• 9.6. Other

10. By End-User

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.1.2. Market Attractiveness Index, By End-User
• 10.2. Hospitals*
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Speciality Clinics
• 10.4. Diagnostic Centers
• 10.5. Other

11. By Region

• 11.1. Introduction
  • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 11.1.2. Market Attractiveness Index, By Region
• 11.2. North America
  • 11.2.1. Introduction
  • 11.2.2. Key Region-Specific Dynamics
  • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Type
  • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.2.7.1. U.S.
    • 11.2.7.2. Canada
    • 11.2.7.3. Mexico
• 11.3. Europe
  • 11.3.1. Introduction
  • 11.3.2. Key Region-Specific Dynamics
  • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Type
  • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.3.7.1. Germany
    • 11.3.7.2. UK
    • 11.3.7.3. France
    • 11.3.7.4. Italy
    • 11.3.7.5. Spain
    • 11.3.7.6. Rest of Europe
• 11.4. South America
  • 11.4.1. Introduction
  • 11.4.2. Key Region-Specific Dynamics
  • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Type
  • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.4.7.1. Brazil
    • 11.4.7.2. Argentina
    • 11.4.7.3. Rest of South America
• 11.5. Asia-Pacific
  • 11.5.1. Introduction
  • 11.5.2. Key Region-Specific Dynamics
  • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Type
  • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.5.7.1. China
    • 11.5.7.2. India
    • 11.5.7.3. Japan
    • 11.5.7.4. Australia
    • 11.5.7.5. Rest of Asia-Pacific
• 11.6. Middle East and Africa
  • 11.6.1. Introduction
  • 11.6.2. Key Region-Specific Dynamics
  • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Type
  • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

• 12.1. Competitive Scenario
• 12.2. Market Positioning/Share Analysis
• 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

• 13.1. EMS Handels Gesellschaft m.b.H.*
  • 13.1.1. Company Overview
  • 13.1.2. Product Portfolio and Description
  • 13.1.3. Financial Overview
  • 13.1.4. Key Developments
• 13.2. KONINKLIJKE PHILIPS N.V.
• 13.3. Medtronic
• 13.4. Allengers
• 13.5. EB NEURO S.P.A.
• 13.6. Shenzhen Delica Medical Equipment Co., Ltd.
• 13.7. Micromed Group
• 13.8. NIHON KOHDEN CORPORATION
• 13.9. Cadwell
• 13.10. Natus Medical Incorporated

LIST NOT EXHAUSTIVE

14. Appendix

• 14.1. About Us and Services
• 14.2. Contact Us